Skip to main content

Table 1 Demographics and participant characteristics by IAC injection type

From: Comparison of efficacy between triamcinolone acetonide and triamcinolone hexacetonide for intraarticular therapy in juvenile idiopathic arthritis: a retrospective analysis

  TA
N = 34 with 124 injections
TH
N = 14 with 41 injections
p value
Relapse time in months (median [IQR]) 3.00 [2.00, 6.00] 11.00 [5.00, 18.00] < 0.001*
Age in years (median [IQR]) 4.88 [2.92, 10.65] 4.83 [3.02, 7.67] 0.901
JIA disease duration in years (median [IQR]) 0.46 [0.19, 2.66] 1.17 [0.44, 4.33] 0.179
Female (%) 27 (79.4) 10 (71.4) 0.708
Ethnicity (%)    0.160
 White 27 (79.4) 13 (92.9)  
 Black 4 (11.8) 0 (0.0)  
 Hispanic 3 (8.8) 0 (0.0)  
 Unknown 0 (0.0) 1 (7.1)  
JIA diagnosis (%)    0.461
 Oligo 24 (70.6) 12 (85.7)  
 Poly 8 (23.5) 1 (7.1)  
 Psoriatic 2 (5.9) 1 (7.1)  
Injections by joint locations (%)    0.051
 Knee 62 (50.0) 24 (58.5)  
 Ankle 31 (25.0) 5 (12.2)  
 Wrist 14 (11.3) 1 (2.4)  
 Elbow 2 (1.6) 1 (2.4)  
 Fingers/toes 14 (11.3) 9 (22.0)  
 Hip 1 (0.8) 0 (0.0)  
 Mid-foot 0 (0.0) 1 (2.4)  
  1. Total sample size is 39 participants with 165 injections. Nine of the 39 participants received both IAC injection types. p values from Mann–Whitney U tests and Fisher’s Exact tests are listed are for the comparison between IAC injection types
  2. IQR interquartile range
  3. *Denotes p value < 0.05